Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.
暂无分享,去创建一个
[1] R. Lefkowitz,et al. β-Arrestin Scaffolding of the ERK Cascade Enhances Cytosolic ERK Activity but Inhibits ERK-mediated Transcription following Angiotensin AT1a Receptor Stimulation* , 2002, The Journal of Biological Chemistry.
[2] H. Loh,et al. Distinct Differences Between Morphine‐ and [d‐Ala2,N‐MePhe4,Gly‐ol5]‐Enkephalin‐ μ‐Opioid Receptor Complexes Demonstrated by Cyclic AMP‐Dependent Protein Kinase Phosphorylation , 1998, Journal of neurochemistry.
[3] Laurent Journot,et al. Differential signal transduction by five splice variants of the PACAP receptor , 1993, Nature.
[4] A. Beaudet,et al. Agonist‐ and antagonist‐induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells , 2003, British journal of pharmacology.
[5] P Ghanouni,et al. Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor* , 2001, The Journal of Biological Chemistry.
[6] Christopher J. Evans,et al. Morphine Activates Opioid Receptors without Causing Their Rapid Internalization* , 1996, The Journal of Biological Chemistry.
[7] R. Lefkowitz,et al. Distinct β-Arrestin- and G Protein-dependent Pathways for Parathyroid Hormone Receptor-stimulated ERK1/2 Activation* , 2006, Journal of Biological Chemistry.
[8] T. Kenakin,et al. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.
[9] R. Mullins,et al. β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2 , 2000, The Journal of cell biology.
[10] Pascale G. Charest,et al. β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[11] L. Lopalco,et al. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. , 2006, Blood.
[12] Robert J. Lefkowitz,et al. Transduction of Receptor Signals by ß-Arrestins , 2005, Science.
[13] Christopher Haslett,et al. Bombesin and Substance P Analogues Differentially Regulate G-protein Coupling to the Bombesin Receptor , 2001, The Journal of Biological Chemistry.
[14] T. Kohout,et al. Differential Desensitization, Receptor Phosphorylation, β-Arrestin Recruitment, and ERK1/2 Activation by the Two Endogenous Ligands for the CC Chemokine Receptor 7* , 2004, Journal of Biological Chemistry.
[15] T. Kenakin,et al. Determining the Potency and Molecular Mechanism of Action of Insurmountable Antagonists , 2006, Journal of Pharmacology and Experimental Therapeutics.
[16] T. Kenakin,et al. The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor , 2005, Molecular Pharmacology.
[17] R. Mailman,et al. 8,9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: A Potent Full Dopamine D1 Agonist Containing a Rigid β-Phenyldopamine Pharmacophore , 1996 .
[18] Arthur Christopoulos,et al. Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.
[19] Terry Kenakin,et al. Efficacy at g-protein-coupled receptors , 2002, Nature Reviews Drug Discovery.
[20] A. Herz,et al. Opioid receptors are coupled tightly to G proteins but loosely to adenylate cyclase in NG108-15 cell membranes. , 1988, Molecular pharmacology.
[21] R. A. Moyer,et al. An Opioid Agonist that Does Not Induce μ-Opioid Receptor—Arrestin Interactions or Receptor Internalization , 2007, Molecular Pharmacology.
[22] L. Miller,et al. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. , 1997, Molecular pharmacology.
[23] S. Edelstein,et al. The Neurokinin A Receptor Activates Calcium and cAMP Responses through Distinct Conformational States* , 2001, The Journal of Biological Chemistry.
[24] H. Mitsuya,et al. Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro , 2004, Journal of Virology.
[25] Sadashiva S Karnik,et al. Multiple Signaling States of G-Protein-Coupled Receptors , 2005, Pharmacological Reviews.
[26] E Meller,et al. Comparative effects of receptor inactivation, 17 beta-estradiol and pertussis toxin on dopaminergic inhibition of prolactin secretion in vitro. , 1992, The Journal of pharmacology and experimental therapeutics.
[27] L. Bačáková,et al. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. , 1997, Molecular pharmacology.
[28] L. Luttrell. Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity , 2007, Journal of Molecular Neuroscience.
[29] Heping Cheng,et al. Spontaneous β2-Adrenergic Signaling Fails To Modulate L-Type Ca2+ Current in Mouse Ventricular Myocytes , 1999 .
[30] G. Mazzocchi,et al. Human pheochromocytomas express orexin receptor type 2 gene and display an in vitro secretory response to orexins A and B. , 2001, The Journal of clinical endocrinology and metabolism.
[31] F. Ehlert,et al. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.
[32] M. B. Ruckle,et al. Constitutively Active μ-Opioid Receptors Inhibit Adenylyl Cyclase Activity in Intact Cells and Activate G-proteins Differently than the Agonist [d-Ala2,N-MePhe4,Gly-ol5]Enkephalin , 2001 .
[33] David R. Sibley,et al. Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.
[34] R. Mailman,et al. Differential Activation of Adenylate Cyclase and Receptor Internalization by Novel Dopamine D1 Receptor Agonists , 2005, Molecular Pharmacology.
[35] A. Howlett,et al. Chemically Distinct Ligands Promote Differential CB1 Cannabinoid Receptor-Gi Protein Interactions , 2005, Molecular Pharmacology.
[36] J. Violin,et al. β-Arrestin 2-Dependent Angiotensin II Type 1A Receptor-Mediated Pathway of Chemotaxis , 2005, Molecular Pharmacology.
[37] P. Leff. Inverse agonism: theory and practice. , 1995, TIPS - Trends in Pharmacological Sciences.
[38] Terry Kenakin,et al. Ligand-selective receptor conformations revisited: the promise and the problem. , 2003, Trends in pharmacological sciences.
[39] J. Kukkonen. Regulation of receptor-coupling to (multiple) G proteins. A challenge for basic research and drug discovery. , 2004, Receptors & channels.
[40] M. Bouvier,et al. Receptor activity‐independent recruitment of βarrestin2 reveals specific signalling modes , 2004, The EMBO journal.
[41] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[42] T. Kenakin. Protean Agonists , 1997, Annals of the New York Academy of Sciences.
[43] Marc Parmentier,et al. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. , 2002, Molecular biology of the cell.
[44] Stephenson Rp. A modification of receptor theory. 1956. , 1997 .
[45] K. Palczewski,et al. Crystal structure of rhodopsin: implications for vision and beyond. , 2001, Current opinion in structural biology.
[46] B. Kobilka,et al. Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. , 1995, The Journal of biological chemistry.
[47] T. Kenakin. New Concepts in Drug Discovery: Collateral Efficacy and Permissive Antagonism , 2005, Nature Reviews Drug Discovery.
[48] Jean Salamero,et al. HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.
[49] P. Wolynes,et al. The energy landscapes and motions of proteins. , 1991, Science.
[50] S. Mundell,et al. Agonist-Selective Mechanisms of μ-Opioid Receptor Desensitization in Human Embryonic Kidney 293 Cells , 2006, Molecular Pharmacology.
[51] R. Maki,et al. Distinct Conformations of the Corticotropin Releasing Factor Type 1 Receptor Adopted following Agonist and Antagonist Binding Are Differentially Regulated* , 2005, Journal of Biological Chemistry.
[52] P. A. Friedman,et al. Activation-independent Parathyroid Hormone Receptor Internalization Is Regulated by NHERF1 (EBP50)* , 2003, Journal of Biological Chemistry.
[53] T. Oas,et al. The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[54] T. Kenakin,et al. The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. , 2000, Molecular pharmacology.
[55] T. Kenakin. Collateral efficacy as a pharmacological problem applied to new drug discovery , 2006, Expert opinion on drug discovery.
[56] Burgen As. Conformational changes and drug action. , 1981 .
[57] Yang Xiang,et al. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. , 2004, The Journal of biological chemistry.
[58] I. Hall,et al. Agonist and Inverse Agonist Actions of β-Blockers at the Human β2-Adrenoceptor Provide Evidence for Agonist-Directed Signaling , 2003 .
[59] J. Rodríguez-Fernández,et al. The Multiple Personalities of the Chemokine Receptor CCR7 in Dendritic Cells1 , 2006, The Journal of Immunology.
[60] B. Roth,et al. The Dynamin-dependent, Arrestin-independent Internalization of 5-Hydroxytryptamine 2A (5-HT2A) Serotonin Receptors Reveals Differential Sorting of Arrestins and 5-HT2A Receptors during Endocytosis* 210 , 2001, The Journal of Biological Chemistry.
[61] B. Roth,et al. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo , 1999, Neuroscience.
[62] Jyrki P. Kukkonen,et al. Agonist trafficking of Gi/o‐mediated α2A‐adrenoceptor responses in HEL 92.1.7 cells , 2001 .
[63] M. Bouvier,et al. Distinct Signaling Profiles of β1 and β2 Adrenergic Receptor Ligands toward Adenylyl Cyclase and Mitogen-Activated Protein Kinase Reveals the Pluridimensionality of Efficacy , 2006, Molecular Pharmacology.
[64] G. Mazzocchi,et al. Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade. , 2001, The Journal of clinical endocrinology and metabolism.
[65] Bryan L Roth,et al. Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists , 2001, Brain Research Bulletin.
[66] Emmanuel Hermans,et al. Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. , 2003, Pharmacology & therapeutics.
[67] M. Lederman,et al. Cutting Edge: Human β Defensin 3—A Novel Antagonist of the HIV-1 Coreceptor CXCR41 , 2006, The Journal of Immunology.
[68] Terry Kenakin,et al. Drug efficacy at G protein-coupled receptors. , 2002, Annual review of pharmacology and toxicology.
[69] L. Hunyady,et al. Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[70] J. Parma,et al. The thyrotropin receptor and the regulation of thyrocyte function and growth. , 1992, Endocrine reviews.
[71] G. Piñeyro,et al. Internalization and Src Activity Regulate the Time Course of ERK Activation by Delta Opioid Receptor Ligands* , 2005, Journal of Biological Chemistry.
[72] C. Woodward. Is the slow exchange core the protein folding core? , 1993, Trends in biochemical sciences.